½ÃÀ庸°í¼­
»óǰÄÚµå
1306028

Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE) ½ÃÀå ±Ô¸ð ¹× µ¿Çâ : ¿ªÇÐ, Áúº´ °ü¸®, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, °æÀï»ç Æò°¡, ¹ÌÃæÁ· ¼ö¿ä, ÀÓ»ó½ÃÇè Àü·«, ¿¹Ãø(-2032³â)

Venous Thromboembolism Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: GlobalData | ÆäÀÌÁö Á¤º¸: ¿µ¹® 122 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ» µî ÁÖ¿ä 7°³ ½ÃÀå(¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ»)ÀÇ Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE) ½ÃÀå ±Ô¸ð´Â 2022³â ¾à 35¾ï 7,000¸¸ ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ ¸»¿¡´Â 46¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, CAGR 2.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ÒÆøÀÇ ¼ºÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¹ß»ýÇÏ´Â ½Å±Ô °æ±¸¿ë Ç×ÀÀ°íÁ¦(NOAC)ÀÇ Æ¯Çã ¸¸·á¿¡ µû¸¥ Á¦³×¸¯ ÀǾàǰÀÇ Ä§½Ä µî¿¡ ±âÀÎÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â 7°³ ÁÖ¿ä ½ÃÀåÀÇ Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE, Venous Thromboembolism) ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÏ¿© ¼öÀÍ ¿¹Ãø, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, °æÀï ±¸µµ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¤¸ÆÇ÷Àü »öÀüÁõ(VTE) : ÁÖ¿ä ¿ä¾à

  • VTE ½ÃÀåÀº 2022³âºÎÅÍ 2032³â±îÁö ÃÖ¼ÒÇÑÀÇ ¼ºÀå¿¡ ±×Ä¥ °Í
  • ±â¾÷µéÀº Á¦11ÀÎÀÚ ¾ïÁ¦Á¦¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè °³¹ß¿¡ ÁýÁß
  • ¾Ï ¶Ç´Â ½ÅÀå Àå¾Ö°¡Àִ ȯÀÚ¸¦ À§ÇÑ ÃÖÀûÀÇ Ä¡·á Àü·«ÀÌ ÇÊ¿ä
  • AbelacimabÀº ¿¹Ãø ±â°£ µ¿¾È ¸ÅÃâ¿¡ Àû´çÈ÷ ±â¿©ÇÒ °Í
  • ÀÇ»çµéÀº ¾î¶»°Ô »ý°¢Çϴ°¡?

Á¦2Àå ¼­·Ð

  • Ã˸Å
  • °ü·Ã º¸°í¼­
  • ÇâÈÄ º¸°í¼­

Á¦3Àå Áúȯ °³¿ä

  • º´ÀÎÇаú º´Å»ý¸®ÇÐ

Á¦4Àå ¿ªÇÐ

  • ÁúȯÀÇ ¹è°æ
  • À§Çè ¿äÀΰú º´Á¸ Áúȯ
  • ¼¼°èÀÇ °ú°Å µ¿Çâ
  • ÁÖ¿ä 7°³ ½ÃÀå ¿¹Ãø ¹æ¹ý
  • Á¤¸ÆÇ÷Àü »öÀüÁõ(VTE) ¿ªÇÐ ¿¹Ãø(2022³â-2032³â)
  • ³í°í

Á¦5Àå Áúº´ °ü¸®

  • Áø´Ü ¹× Ä¡·á °³¿ä
  • Áúº´ °ü¸®¿¡ °üÇÑ KOL ÀλçÀÌÆ®

Á¦6Àå °æÀï Æò°¡

  • °³¿ä

Á¦7Àå ¹ÌÃæÁ· ¿ä±¸¿Í ±âȸ Æò°¡

  • °³¿ä
  • ÃâÇ÷ ¸®½ºÅ© °æ°¨
  • ¾Ï ȯÀÚ¿¡ ´ëÇÑ ÃÖÀûÀÇ Ä¡·á
  • ½ÅÀå Àå¾Ö ¹× ½ÅºÎÀü ȯÀÚ¿¡ ´ëÇÑ ÃÖÀûÀÇ Ä¡·á
  • ºñ°æ±¸ ¿ä¹ý¿¡ ¼ö¹ÝÇÏ´Â ÇÕº´Áõ
  • ÀÇ»ç¿Í ȯÀÚ ±³À° °³¼±

Á¦8Àå ¿¬±¸°³¹ß Àü·«

  • °³¿ä
  • ÀÓ»ó½ÃÇè ¼³°è

Á¦9Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡

  • °³¿ä
  • ÀÓ»ó °³¹ß ÁßÀÎ À¯¸ÁÇÑ ¾àǰ

Á¦10Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®

  • °³¿ä
  • °æÀï Æò°¡

Á¦11Àå ÇöÀç¿Í ÇâÈÄ ±â¾÷

  • °³¿ä
  • °Å·¡ °áÁ¤ µ¿Çâ

Á¦12Àå ½ÃÀå Àü¸Á

  • ¼¼°è ½ÃÀå
  • ¹Ì±¹
  • À¯·´ 5°³±¹
  • ÀϺ»

Á¦13Àå ºÎ·Ï

LSH 23.07.18

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Venous Thromboembolism (VTE) market through 2032.

According to GlobalData estimates, 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. The US is the most significant contributor to that revenue, accounting for 80.8% of sales. This can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period. This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period. Furthermore, although there is one late-stage pipeline therapy that is expected to launch in the US and 5EU during the forecast period, the drug will only capture a small share of the market due to its high cost, subcutaneous method of administration, long half-life, and lack of strong clinical trial data.

Report deliverables include a Pdf and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032.

  • 2022 base year sales within the VTE market are approximately $3.57 billion across the 7MM detailed in this report. GlobalData estimates that the VTE market will grow at a compound annual growth rate (CAGR) of 2.6% to reach $4.62 billion by the end of the forecast period.
  • This minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period as well as only one late-stage pipeline therapy that will only capture a small share of the market due to its high cost, subcutaneous method of administration, and lack of strong clinical trial data.

Scope

  • Overview of VTE, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized VTE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the VTE market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for VTE treatment and prophylaxis. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Venous Thromboembolism: Executive Summary

  • 1.1 The VTE market will experience minimal growth between 2022 and 2032
  • 1.2 Companies are focusing clinical trial development on factor XI inhibitors
  • 1.3 Optimal treatment strategies for patients with cancer or renal impairment are needed
  • 1.4 Abelacimab to contribute moderately to sales during the forecast period
  • 1.5 What do physicians think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related reports
  • 2.3 Upcoming reports

3 Disease Overview

  • 3.1 Etiology and pathophysiology

4 Epidemiology

  • 4.1 Disease background
  • 4.2 Risk factors and comorbidities
  • 4.3 Global and historical trends
  • 4.4 7MM forecast methodology
  • 4.5 Epidemiological forecast for venous thromboembolism (VTE) (2022-32)
  • 4.6 Discussion

5 Disease Management

  • 5.1 Diagnosis and treatment overview
  • 5.2 Key opinion leader insights on disease management

6 Competitive Assessment

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Mitigating bleeding risk
  • 7.3 Optimal treatment for cancer patients
  • 7.4 Optimal treatment for patients with renal impairment and renal failure
  • 7.5 Complications associated with parenteral therapies
  • 7.6 Improved education among physicians and patients

8 R&D Strategies

  • 8.1 Overview
  • 8.2 Clinical trials design

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive assessment

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-making trends

12 Market Outlook

  • 12.1 Global markets
  • 12.2 US
  • 12.3 5EU
  • 12.4 Japan

13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology
  • 13.4 Primary research - key opinion leaders interviewed for this report
  • 13.5 Primary research - prescriber survey
  • 13.6 About the Authors
  • Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦